MAbs could alter PDLI core program
Protein Design Labs Inc. acquired from Sandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp. two human antiviral monoclonal antibodies that will become its lead clinical candidates, as well as the technology to produce them. That technology will be compared to PDLI's own Smart antibody technology and could supplant it